<DOC>
	<DOCNO>NCT01749956</DOCNO>
	<brief_summary>The purpose Phase II study investigate antiangiogenic agent , aflibercept , combination chemoradiation preoperative treatment patient stage II/III rectal cancer , follow 4 month FOLFOX6 plus aflibercept adjuvantly .</brief_summary>
	<brief_title>5-FU , Aflibercept , Radiation ( RT ) Preoperative Postoperative Patients With Stage II/III Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>1 . Patients histologically confirm stage II III rectal cancer ( adenocarcinoma ) 2 . Patients must candidate preoperative chemoradiation 3 . Male female patient ≥18 yearsofage 4 . Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) score 0 1 5 . Adequate hematologic , liver renal function 6 . Male patient willing use adequate contraceptive measure 7 . Female patient childbearing potential , female patient childbearing potential agree use adequate contraceptive measure , breastfeeding , negative serum urine pregnancy test &lt; 7 day prior start treatment 8 . Life expectancy ≥12 week 9 . Willingness ability comply trial followup procedures 10 . Ability understand nature trial give write informed consent . 1 . Treatment prior chemotherapy radiation rectal cancer . 2 . Patients receive investigational agent within 28 day prior Day 1 study . 3 . Known human immunodeficiency virus positive hepatitis B C positive 4 . Women pregnant breastfeed 5 . History acute myocardial infarction within previous 6 month , uncontrolled hypertension ( blood pressure &gt; 150/100 mmHg and/or diastolic blood pressure &gt; 100 mmHg ) , unstable angina , New York Heart Association Grade 2 great congestive heart failure , serious cardiac arrhythmia require medication ( exclude atrial fibrillation ) , ≥ Grade 2 peripheral vascular disease . 6 . History hypertensive crisis hypertensive encephalopathy . 7 . History stroke transient ischemic attack within past 6 month . 8 . Significant vascular disease ( eg , aortic aneurysm require surgical repair recent peripheral arterial thrombosis ) within 6 month prior initiation therapy . 9 . History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 6 month . 10 . Patients symptomatic sensory peripheral neuropathy ( Grade 2 ) . 11 . Patients may receive agent , either investigational market , act primary antiangiogenic mechanism . 12 . Prior malignancy ( except adequately treat basalcell squamouscell skin cancer , situ carcinoma , low grade [ Gleason score 3+3 less ] localized prostate cancer ) past 5 year . 13 . Patients active concurrent infection patient serious underlying medical condition . 14 . Patients receive fulldose oral parenteral/SC anticoagulation must stable dose schedule prior enrollment ; coumadin dose must stable 1 week . If achieve , patient ineligible enrollment . 15 . Major surgical procedure significant traumatic injury within 28 day prior study initiation , anticipation need major surgical procedure course study . 16 . Core biopsy minor surgical procedure , exclude placement vascular access device , within 7 day prior initiation therapy . 17 . Patients proteinuria , demonstrate urine protein 2+ great screening . If 2+ great proteinuria , 24hour urine obtain , result &lt; 1 gm/24 hour , patient eligible . 18 . Any nonhealing wound , ulcer , bone fracture . 19 . Any clinical evidence history bleed diathesis significant coagulopathy ( absence therapeutic anticoagulation ) . 20 . History hemoptysis ( ≥½ teaspoon bright red blood per episode ) within 1 month prior initiation therapy . 21 . History disease , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Rectal Cancer</keyword>
	<keyword>Chemoradiation</keyword>
	<keyword>Aflibercept</keyword>
	<keyword>Surgery</keyword>
</DOC>